Commercial RiskRisks include commercial risk with respect to Enhanze, particularly in the multiple myeloma indication, which is dynamic and rapidly evolving.
CompetitionIf a competitor such as Alteogen or XERS announces major new business for its version of hyaluronidase, it would be a negative for investor perception.
Market ThreatAlthough it is unclear when Huons Lab would become a competitive threat to ENHANZE in the US & EU, the announcement highlights that multiple companies are pursuing copycat versions of ENHANZE.